Trastuzumab and Biosimilars

January 26, 2026

About Trastuzumab [HER2+ antibody]

Trastuzumab blocks the activity of HER2 and triggers a type of immune reaction that kills cells that have a lot of HER2. It is a type of targeted therapy drug called a monoclonal antibody.

Trastuzumab is approved to be used alone or with other drugs to treat:

  • Breast cancer that is HER2 positive (HER2+).
  • Stomach adenocarcinoma or gastroesophageal junction adenocarcinoma that has metastasized.

Commercial Products

AttributesRD codeBrand NameApprovedOwnerAreaWebSite
OriginatorJ9355Herceptin®1998 RocheUSAroche.com
BiosimilarHLX02CNN:汉曲优®2020
Henlius (CNN:复宏汉霖)
Chinahenlius.com
BiosimilarHS022CNN:安瑞泽®2023BioRay(CNN:博锐生物>海正生物>贝达药业)Chinabioraypharm.com
BiosimilarTQ-B211CNN:赛妥®2023CHIATHAI TIANQIONG(CNN:正大天晴药业)Chinacttq.com
BiosimilarAK-HER2CNN:安赛汀®2023AnKeBio(CNN:安科生物)Chinaankebio.com
BiosimilarQL1701CNN:安曲妥2024QiLu Pharma(CNN:齐鲁制药)Chinaqilu-pharma.com

Business Cooperation

  • You wish to purchase this product (Trastuzumab).
  • Do you want to obtain the distribution rights for this product (Trastuzumab)?